InsidersTradesSigma
Ekso Bionics Holdings, INC. Stock: price and management transactions · United States · SEC (Form 4)
Follow the Ekso Bionics Holdings, INC. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Ekso Bionics Holdings, INC. has logged 93 insider filings. Market capitalisation: €42m. The latest transaction was reported on 17 February 2026 (Acquisition). Among the most active insiders: SHERMAN STEVEN. Every trade is accessible without an account.
93
Insider Decl.
0
Thresholds
€821,535
9 ops.
Buy Volume
€256,641
23 ops.
Sell Volume
40Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 24,061 of 25,451 companies
16.4
score / 100
Value8
Quality25
FCF yld-29%
Earn yld-28%
EV/EBITDA·
ROE-108%
Gross mgn53%
Net mgn-91%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 17 February 2026
Declarations93 total
194 shares@ US$9.85520.2% of flowCommon StockSEC:0001251859-26-000010:0
Ideal exit: 3 Nov 2026 (T+270)
4,800 shares@ US$9.96255.0% of flowCommon StockSEC:0001251859-26-000010:1
Ideal exit: 6 Nov 2026 (T+270)
10,200 shares@ US$9.92410.4% of flowCommon StockSEC:0001251859-26-000010:2
Ideal exit: 7 Nov 2026 (T+270)
20,611 shares@ US$9.692420.6% of flowCommon StockSEC:0001251859-26-000010:3
Ideal exit: 8 Nov 2026 (T+270)
8,908 shares@ US$9.18448.4% of flowCommon StockSEC:0001251859-26-000010:4
Ideal exit: 9 Nov 2026 (T+270)
30,124 shares@ US$9.68830.1% of flowCommon StockSEC:0001251859-26-000010:5
Ideal exit: 9 Nov 2026 (T+270)
11,092 shares@ US$9.142910.5% of flowCommon StockSEC:0001251859-26-000010:6
Ideal exit: 10 Nov 2026 (T+270)
16,100 shares@ US$8.961114.9% of flowCommon StockSEC:0001251859-26-000010:7
Ideal exit: 10 Nov 2026 (T+270)
1,320 shares@ US$9.250.034% mcap33.2% of flowCommon StockSEC:0001437749-26-000801:0
1,320 shares@ US$9.2533.2% of flowCommon StockSEC:0001437749-26-000801
270 shares@ US$4.703.5% of flowCommon StockSEC:0001437749-25-037391
270 shares@ US$4.700.0035% mcap3.5% of flowCommon StockSEC:0001437749-25-037391:0
1,238 shares@ US$4.700.016% mcap50.0% of flowCommon StockSEC:0001437749-25-037390:0
1,238 shares@ US$4.7050.0% of flowCommon StockSEC:0001437749-25-037390
236,202 shares0Common StockSEC:0001437749-25-017682:0
236,202 shares0Common StockSEC:0001437749-25-017683:0
236,202 shares0Common StockSEC:0001437749-25-017685:0
236,202 shares0Common StockSEC:0001437749-25-017686:0
5,590 sharesCommon StockSEC:0001437749-25-008292:0
24,248 sharesCommon StockSEC:0001437749-25-008294:0
24,248 sharesCommon StockSEC:0001437749-25-008293:0
78,217 shares0Common StockSEC:0001437749-24-021281:0
78,217 shares0Common StockSEC:0001437749-24-021278:0
78,217 shares0Common StockSEC:0001437749-24-021276:0
78,217 shares0Common StockSEC:0001437749-24-021274:0
25 of 93 declarations
About Ekso Bionics Holdings, INC.
Ekso Bionics Holdings, Inc. is a U.S.-based robotics and medical technology company listed on the Nasdaq Capital Market in the United States under the ticker EKSO. The company was founded in 2005 and is headquartered in the San Francisco Bay Area, with operating roots in San Rafael, California. Its core business is the design, development, and commercialization of exoskeletons and complementary products intended to augment human strength, endurance, and mobility. For investors, Ekso Bionics sits at the intersection of medtech, robotics, and assistive technology. The company’s commercial model is centered on two end markets: Enterprise Health and Personal Health. In Enterprise Health, Ekso’s flagship product is EksoNR, a wearable robotic exoskeleton used in clinical rehabilitation settings for patients recovering from spinal cord injury, stroke, traumatic brain injury, and multiple sclerosis. The company also offers Ekso Indego Therapy, a lightweight, modular, lower-limb powered exoskeleton used in rehabilitation and wellness applications. In Personal Health, Ekso Indego Personal is designed to help individuals with mobility impairments—particularly people with spinal cord injuries—achieve overground walking in home and community settings. Ekso also has an industrial exposure through Ekso EVO, an upper-body wearable exoskeleton aimed at reducing worker fatigue and injury risk in repetitive overhead tasks. The company targets industries such as aerospace, automotive, general manufacturing, and selected construction trades. Beyond hardware sales, Ekso provides support and service offerings through EksoCare, including extended warranty, loaner devices, clinical support, and training. This service layer can help increase customer stickiness and support recurring revenue characteristics over time. From a competitive standpoint, Ekso operates in an emerging market where adoption depends on clinical evidence, reimbursement coverage, regulatory approvals, and customer education. Its positioning is supported by FDA clearances, a long operating history since 2005, and a focused product portfolio. A notable recent development was Medicare reimbursement approval for Ekso Indego Personal in 2024, which may expand access in the U.S. patient population. In 2025, the company announced new distribution for Indego Personal, joined the NVIDIA Connect program to develop AI capabilities related to human motion, and advanced its European footprint through CE/MDR certification. However, the company remains a small-cap, high-risk name with ongoing cash burn and reliance on external financing or strategic partnerships to fund growth and product development.
